Copyright Reports & Markets. All rights reserved.

Global Cefotaxime Sodium API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Cefotaxime Sodium API Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 ChP
    • 1.3.3 USP
    • 1.3.4 EP
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Cefotaxime Sodium API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Single Injection
    • 1.4.3 Compound Injection
  • 1.5 Global Cefotaxime Sodium API Market Size & Forecast
    • 1.5.1 Global Cefotaxime Sodium API Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Cefotaxime Sodium API Sales Quantity (2021-2032)
    • 1.5.3 Global Cefotaxime Sodium API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 REYOUNG
    • 2.1.1 REYOUNG Details
    • 2.1.2 REYOUNG Major Business
    • 2.1.3 REYOUNG Cefotaxime Sodium API Product and Services
    • 2.1.4 REYOUNG Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 REYOUNG Recent Developments/Updates
  • 2.2 Nectar Lifesciences
    • 2.2.1 Nectar Lifesciences Details
    • 2.2.2 Nectar Lifesciences Major Business
    • 2.2.3 Nectar Lifesciences Cefotaxime Sodium API Product and Services
    • 2.2.4 Nectar Lifesciences Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Nectar Lifesciences Recent Developments/Updates
  • 2.3 Medya Pharma
    • 2.3.1 Medya Pharma Details
    • 2.3.2 Medya Pharma Major Business
    • 2.3.3 Medya Pharma Cefotaxime Sodium API Product and Services
    • 2.3.4 Medya Pharma Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Medya Pharma Recent Developments/Updates
  • 2.4 Sandoz
    • 2.4.1 Sandoz Details
    • 2.4.2 Sandoz Major Business
    • 2.4.3 Sandoz Cefotaxime Sodium API Product and Services
    • 2.4.4 Sandoz Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sandoz Recent Developments/Updates
  • 2.5 Kelun
    • 2.5.1 Kelun Details
    • 2.5.2 Kelun Major Business
    • 2.5.3 Kelun Cefotaxime Sodium API Product and Services
    • 2.5.4 Kelun Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Kelun Recent Developments/Updates
  • 2.6 NCPC
    • 2.6.1 NCPC Details
    • 2.6.2 NCPC Major Business
    • 2.6.3 NCPC Cefotaxime Sodium API Product and Services
    • 2.6.4 NCPC Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 NCPC Recent Developments/Updates
  • 2.7 Aurobindo Pharma
    • 2.7.1 Aurobindo Pharma Details
    • 2.7.2 Aurobindo Pharma Major Business
    • 2.7.3 Aurobindo Pharma Cefotaxime Sodium API Product and Services
    • 2.7.4 Aurobindo Pharma Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Aurobindo Pharma Recent Developments/Updates
  • 2.8 United Laboratories
    • 2.8.1 United Laboratories Details
    • 2.8.2 United Laboratories Major Business
    • 2.8.3 United Laboratories Cefotaxime Sodium API Product and Services
    • 2.8.4 United Laboratories Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 United Laboratories Recent Developments/Updates
  • 2.9 Orchid Pharma
    • 2.9.1 Orchid Pharma Details
    • 2.9.2 Orchid Pharma Major Business
    • 2.9.3 Orchid Pharma Cefotaxime Sodium API Product and Services
    • 2.9.4 Orchid Pharma Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Orchid Pharma Recent Developments/Updates
  • 2.10 CSPC
    • 2.10.1 CSPC Details
    • 2.10.2 CSPC Major Business
    • 2.10.3 CSPC Cefotaxime Sodium API Product and Services
    • 2.10.4 CSPC Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 CSPC Recent Developments/Updates
  • 2.11 Kopran
    • 2.11.1 Kopran Details
    • 2.11.2 Kopran Major Business
    • 2.11.3 Kopran Cefotaxime Sodium API Product and Services
    • 2.11.4 Kopran Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Kopran Recent Developments/Updates
  • 2.12 Covalent
    • 2.12.1 Covalent Details
    • 2.12.2 Covalent Major Business
    • 2.12.3 Covalent Cefotaxime Sodium API Product and Services
    • 2.12.4 Covalent Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Covalent Recent Developments/Updates
  • 2.13 ACS Dobfar
    • 2.13.1 ACS Dobfar Details
    • 2.13.2 ACS Dobfar Major Business
    • 2.13.3 ACS Dobfar Cefotaxime Sodium API Product and Services
    • 2.13.4 ACS Dobfar Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 ACS Dobfar Recent Developments/Updates
  • 2.14 Dawnrays
    • 2.14.1 Dawnrays Details
    • 2.14.2 Dawnrays Major Business
    • 2.14.3 Dawnrays Cefotaxime Sodium API Product and Services
    • 2.14.4 Dawnrays Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Dawnrays Recent Developments/Updates
  • 2.15 Sterile India
    • 2.15.1 Sterile India Details
    • 2.15.2 Sterile India Major Business
    • 2.15.3 Sterile India Cefotaxime Sodium API Product and Services
    • 2.15.4 Sterile India Cefotaxime Sodium API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Sterile India Recent Developments/Updates

3 Competitive Environment: Cefotaxime Sodium API by Manufacturer

  • 3.1 Global Cefotaxime Sodium API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Cefotaxime Sodium API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Cefotaxime Sodium API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Cefotaxime Sodium API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Cefotaxime Sodium API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Cefotaxime Sodium API Manufacturer Market Share in 2025
  • 3.5 Cefotaxime Sodium API Market: Overall Company Footprint Analysis
    • 3.5.1 Cefotaxime Sodium API Market: Region Footprint
    • 3.5.2 Cefotaxime Sodium API Market: Company Product Type Footprint
    • 3.5.3 Cefotaxime Sodium API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Cefotaxime Sodium API Market Size by Region
    • 4.1.1 Global Cefotaxime Sodium API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Cefotaxime Sodium API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Cefotaxime Sodium API Average Price by Region (2021-2032)
  • 4.2 North America Cefotaxime Sodium API Consumption Value (2021-2032)
  • 4.3 Europe Cefotaxime Sodium API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Cefotaxime Sodium API Consumption Value (2021-2032)
  • 4.5 South America Cefotaxime Sodium API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Cefotaxime Sodium API Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 5.2 Global Cefotaxime Sodium API Consumption Value by Type (2021-2032)
  • 5.3 Global Cefotaxime Sodium API Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 6.2 Global Cefotaxime Sodium API Consumption Value by Application (2021-2032)
  • 6.3 Global Cefotaxime Sodium API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 7.2 North America Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 7.3 North America Cefotaxime Sodium API Market Size by Country
    • 7.3.1 North America Cefotaxime Sodium API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Cefotaxime Sodium API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 8.2 Europe Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Cefotaxime Sodium API Market Size by Country
    • 8.3.1 Europe Cefotaxime Sodium API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Cefotaxime Sodium API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Cefotaxime Sodium API Market Size by Region
    • 9.3.1 Asia-Pacific Cefotaxime Sodium API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Cefotaxime Sodium API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 10.2 South America Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 10.3 South America Cefotaxime Sodium API Market Size by Country
    • 10.3.1 South America Cefotaxime Sodium API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Cefotaxime Sodium API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Cefotaxime Sodium API Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Cefotaxime Sodium API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Cefotaxime Sodium API Market Size by Country
    • 11.3.1 Middle East & Africa Cefotaxime Sodium API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Cefotaxime Sodium API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Cefotaxime Sodium API Market Drivers
  • 12.2 Cefotaxime Sodium API Market Restraints
  • 12.3 Cefotaxime Sodium API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Cefotaxime Sodium API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Cefotaxime Sodium API
  • 13.3 Cefotaxime Sodium API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Cefotaxime Sodium API Typical Distributors
  • 14.3 Cefotaxime Sodium API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Cefotaxime Sodium API market size was valued at US$ 102 million in 2025 and is forecast to a readjusted size of US$ 96 million by 2032 with a CAGR of -0.8% during review period.
    Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
    The Cefotaxime Sodium API market is primarily driven by the rising prevalence of bacterial infections and the increasing global demand for third-generation cephalosporin antibiotics. Cefotaxime sodium, known for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria, is widely used in the treatment of serious infections such as respiratory tract infections, urinary tract infections, meningitis, and septicemia. With growing concerns over antimicrobial resistance, physicians and healthcare providers continue to rely on proven β-lactam antibiotics like cefotaxime in hospital settings. The API is in consistent demand across emerging markets where infectious diseases remain a significant public health challenge, particularly in Asia, Africa, and parts of Latin America. Furthermore, the expansion of generic drug manufacturing, especially in India and China, has boosted the demand for cost-effective, high-quality cefotaxime sodium APIs for formulation into injectable and oral dosage forms. Favorable regulatory frameworks supporting antibiotic production and the inclusion of cefotaxime on the WHO’s Essential Medicines List further reinforce its market relevance. Technological advancements in fermentation and purification processes have also improved production efficiency, helping API manufacturers scale up operations and meet global supply needs.
    Despite strong clinical utility, the Cefotaxime Sodium API market faces several challenges that may hinder its long-term growth. One major issue is the increasing regulatory scrutiny over antibiotic manufacturing processes, particularly concerning environmental compliance, waste disposal, and antimicrobial resistance mitigation. Several large manufacturing hubs, especially in developing countries, have faced regulatory warnings or closures due to non-compliance with Good Manufacturing Practices (GMP) or environmental norms. Additionally, pricing pressures in the generic antibiotic segment are intense, with fierce competition among API suppliers leading to margin erosion. The commoditization of cephalosporin APIs like cefotaxime has made it difficult for manufacturers to differentiate their products or command premium prices. There are also supply chain vulnerabilities caused by dependence on a limited number of raw material suppliers and geopolitical tensions affecting trade flows. Moreover, global efforts to reduce overuse of antibiotics in both human and veterinary medicine—while necessary from a public health perspective—may lead to more conservative prescribing practices, indirectly impacting volume demand. Manufacturers also face the challenge of meeting varied pharmacopeial standards (e.g., USP, EP, IP), requiring multiple validation processes and regulatory submissions. To stay competitive, API producers must invest in cleaner technologies, supply chain resilience, and diversification strategies while balancing cost-efficiency and regulatory compliance.
    This report is a detailed and comprehensive analysis for global Cefotaxime Sodium API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Cefotaxime Sodium API market size and forecasts, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/MT), 2021-2032
    Global Cefotaxime Sodium API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/MT), 2021-2032
    Global Cefotaxime Sodium API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/MT), 2021-2032
    Global Cefotaxime Sodium API market shares of main players, shipments in revenue ($ Million), sales quantity (MT), and ASP (USD/MT), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Cefotaxime Sodium API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Cefotaxime Sodium API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, NCPC, Aurobindo Pharma, United Laboratories, Orchid Pharma, CSPC, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Cefotaxime Sodium API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    ChP
    USP
    EP
    Market segment by Application
    Single Injection
    Compound Injection
    Major players covered
    REYOUNG
    Nectar Lifesciences
    Medya Pharma
    Sandoz
    Kelun
    NCPC
    Aurobindo Pharma
    United Laboratories
    Orchid Pharma
    CSPC
    Kopran
    Covalent
    ACS Dobfar
    Dawnrays
    Sterile India
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Cefotaxime Sodium API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Cefotaxime Sodium API, with price, sales quantity, revenue, and global market share of Cefotaxime Sodium API from 2021 to 2026.
    Chapter 3, the Cefotaxime Sodium API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Cefotaxime Sodium API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Cefotaxime Sodium API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Cefotaxime Sodium API.
    Chapter 14 and 15, to describe Cefotaxime Sodium API sales channel, distributors, customers, research findings and conclusion.

    Buy now